Ieq Capital LLC Invests $12.45 Million in Insulet Corporation $PODD

Ieq Capital LLC bought a new stake in Insulet Corporation (NASDAQ:PODD) in the second quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The firm bought 81,786 shares of the medical instruments supplier’s stock, valued at approximately $12,452,000. Ieq Capital LLC owned approximately 0.12% of Insulet at the end of the most recent quarter.

Several other institutional investors have also recently made changes to their positions in PODD. Larson Financial Group LLC increased its holdings in Insulet by 114.6% during the fourth quarter. Larson Financial Group LLC now owns 88 shares of the medical instruments supplier’s stock worth $25,000 after buying an additional 47 shares during the last quarter. University of Texas Texas AM Investment Management Co. acquired a new stake in shares of Insulet during the 4th quarter worth about $26,000. DV Equities LLC bought a new stake in shares of Insulet during the 4th quarter worth about $28,000. Elyxium Wealth LLC acquired a new position in Insulet in the 4th quarter valued at about $28,000. Finally, Mcguire Capital Advisors Inc. acquired a new position in Insulet in the 4th quarter valued at about $29,000.

Insulet News Summary

Here are the key news stories impacting Insulet this week:

• Neutral Sentiment: Pomerantz said a class action has been filed in the U.S. District Court for the District of Massachusetts under docket 26-cv-13062. The proposed class generally covers investors who purchased Insulet securities between February 21, 2025, and May 26, 2026, and seeks damages under Sections 10(b) and 20(a) of the Securities Exchange Act. Pomerantz class action filing
• Neutral Sentiment: Several law firms—including DJS Law Group, Schall Brown & Schwartz, Robbins Geller, Faruqi & Faruqi, Rosen, Bronstein Gewirtz & Grossman, and Bernstein Liebhard—reminded shareholders of an August 31 deadline to seek appointment as lead plaintiff. These announcements are primarily investor solicitations rather than new operational developments. Robbins Geller investor deadline
• Negative Sentiment: The allegations center on purportedly false or misleading statements about Insulet’s manufacturing quality and product safety. One investor notice linked the claims to two Omnipod medical-device corrections and reported substantial share-price declines following corrective disclosures. If the case advances, Insulet could face litigation expenses, potential damages, reputational harm, and additional scrutiny of its products and disclosures. Insulet shareholder lawsuit allegations

Analyst Upgrades and Downgrades

Several research firms have weighed in on PODD. Citigroup increased their price target on shares of Insulet from $165.00 to $172.00 and gave the company a “neutral” rating in a report on Wednesday, July 8th. TD Cowen decreased their target price on Insulet from $294.00 to $144.00 and set a “hold” rating on the stock in a research report on Thursday, August 6th. BTIG Research lowered Insulet from a “buy” rating to a “neutral” rating in a research note on Thursday, August 6th. Truist Financial reissued a “hold” rating and set a $153.00 price target (down from $210.00) on shares of Insulet in a report on Wednesday, August 5th. Finally, Deutsche Bank Aktiengesellschaft assumed coverage on Insulet in a research note on Tuesday, June 23rd. They issued a “buy” rating and a $190.00 price target for the company. Fourteen equities research analysts have rated the stock with a Buy rating, eleven have assigned a Hold rating and two have issued a Sell rating to the stock. Based on data from MarketBeat, the stock presently has a consensus rating of “Hold” and a consensus price target of $195.40.

Insulet Stock Performance

Shares of NASDAQ:PODD opened at $148.16 on Friday. Insulet Corporation has a 1 year low of $126.40 and a 1 year high of $354.88. The company’s 50 day simple moving average is $154.67 and its 200 day simple moving average is $184.81. The company has a debt-to-equity ratio of 0.65, a current ratio of 2.48 and a quick ratio of 1.83. The stock has a market capitalization of $10.27 billion, a price-to-earnings ratio of 27.69, a price-to-earnings-growth ratio of 1.17 and a beta of 1.10.

Insulet (NASDAQ:PODD) last posted its quarterly earnings results on Wednesday, August 5th. The medical instruments supplier reported $1.66 EPS for the quarter, topping analysts’ consensus estimates of $1.47 by $0.19. The company had revenue of $801.70 million during the quarter, compared to analysts’ expectations of $787.39 million. Insulet had a return on equity of 29.29% and a net margin of 12.29%.Insulet’s revenue was up 23.5% on a year-over-year basis. During the same quarter in the previous year, the firm earned $1.17 EPS. Insulet has set its FY 2026 guidance at 6.460- EPS. As a group, research analysts predict that Insulet Corporation will post 6.51 EPS for the current fiscal year.

Insider Transactions at Insulet

In related news, Director Timothy C. Stonesifer acquired 2,790 shares of the stock in a transaction that occurred on Wednesday, June 3rd. The stock was acquired at an average cost of $143.51 per share, for a total transaction of $400,392.90. Following the transaction, the director directly owned 9,041 shares in the company, valued at $1,297,473.91. This trade represents a 44.63% increase in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. 0.36% of the stock is currently owned by corporate insiders.

About Insulet

Insulet Corporation is a medical device company headquartered in Acton, Massachusetts, that develops, manufactures and sells insulin-delivery systems for people with diabetes. The company’s core business is the design and commercialization of its Omnipod family of tubeless, wearable insulin pumps and the consumable Pods that deliver insulin. Insulet’s products aim to simplify insulin delivery for people with type 1 diabetes and insulin-requiring type 2 diabetes by offering an alternative to traditional insulin pens and tethered pump systems.

The company’s product portfolio includes the Omnipod System line—disposable, waterproof Pods that adhere to the skin and deliver insulin—and the associated controllers and mobile applications used to program and monitor insulin delivery.